---
schema_version: "secwatch.filing_event.v1"
accession: "0001728205-24-000058"
form_type: "8-K"
ticker: null
cik: "0001728205"
company_name: "Piedmont Lithium Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:31:21.693107+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Piedmont Lithium Q1 2024 revenue $13.4M, net loss $23.6M; NAL record production, Carolina Lithium permit

## Summary
- Q1 revenue $13.4M on ~15,500 dmt spodumene concentrate; net loss $23.6M ($1.22 diluted EPS); adjusted net loss $11.9M ($0.61).
- NAL record quarterly production 40,439 dmt; lithium recoveries 69% in March; full run-rate expected H2 2024.
- Carolina Lithium mining permit received May 2024; accelerating funding discussions with strategic partners.
- Cash $71.4M as of March 31, 2024; working capital nearly doubled from year-end 2023.
- 2024 outlook: full-year shipments ~126,000 dmt weighted to H2; H2 shipments to more than double H1; investments down >50% H2 vs H1.

## SEC filing metadata
- accession: 0001728205-24-000058
- form_type: 8-K
- cik: 0001728205
- company_name: Piedmont Lithium Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728205/000172820524000058/0001728205-24-000058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728205/000172820524000058/pll-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001728205-24-000058
- JSON: https://secwatch.observer/filing/0001728205-24-000058.json
- Plain text: https://secwatch.observer/filing/0001728205-24-000058.txt

## Key facts
- Earnings Releases
  Piedmont Lithium Inc. reported quarter ended March 31, 2024 results: revenue $13.4 million, net income ($23.6 million), EPS ($1.22) per diluted share.
  - Period: quarter ended March 31, 2024
  - Revenue: $13.4 million
  - Net income: ($23.6 million)
  - EPS: ($1.22) per diluted share
  - Result: reported results
  source text: Revenue of $13.4 million on sales of approximately 15,500 dmt of spodumene concentrate • $71.4 million in cash as of March 31, 2024; working capital nearly doubled from 2023 year end • 2024 outlook for shipments to more than double and investments to decrease more than 50% in H2’24 vs. H1’24
  evidence_url: https://www.sec.gov/Archives/edgar/data/1728205/000172820524000058/0001728205-24-000058-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.